Golden ARCHES.

Enzalutamide combined with androgen deprivation therapy (ADT) is a treatment option for men with metastatic, castration sensitive prostate cancer (mCSPC). Initial results of the ARCHES trial showed that the addition of enzalutamide to ADT improved radiographic progression free survival. However, the secondary endpoint of overall survival (OS) was not mature. In this updated report, the addition of enzalutamide to ADT significantly reduced the risk of death by 34%. Median OS was not yet reached in the enzalutamide arm and was 48 months in the ADT alone arm. At 48 months, OS was 71% with ADT+enzalutamide compared to 57% with ADT alone. | Armstrong, J Clin Oncol 2022